Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.
Montebello M, Jefferies M, Mills L, Bruno R, Copeland J, McGregor I, Rivas C, Jackson MA, Silsbury C, Dunlop A, Lintzeris N; Agonist Replacement For Cannabis Dependence Study Group (ARC-D). Montebello M, et al. Among authors: jefferies m. Drug Alcohol Depend. 2022 May 1;234:109388. doi: 10.1016/j.drugalcdep.2022.109388. Epub 2022 Mar 3. Drug Alcohol Depend. 2022. PMID: 35316689 Clinical Trial.
Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N; Agonist Replacement for Cannabis Dependence (ARCD) study group. Bhardwaj AK, et al. BMC Psychiatry. 2018 May 18;18(1):140. doi: 10.1186/s12888-018-1682-2. BMC Psychiatry. 2018. PMID: 29776349 Free PMC article.
Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial.
Lintzeris N, Bhardwaj A, Mills L, Dunlop A, Copeland J, McGregor I, Bruno R, Gugusheff J, Phung N, Montebello M, Chan T, Kirby A, Hall M, Jefferies M, Luksza J, Shanahan M, Kevin R, Allsop D; Agonist Replacement for Cannabis Dependence (ARCD) study group. Lintzeris N, et al. Among authors: jefferies m. JAMA Intern Med. 2019 Sep 1;179(9):1242-1253. doi: 10.1001/jamainternmed.2019.1993. JAMA Intern Med. 2019. PMID: 31305874 Free PMC article.
Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
Lintzeris N, Monds LA, Bravo M, Read P, Harrod ME, Gilliver R, Wood W, Nielsen S, Dietze PM, Lenton S, Shanahan M, Jauncey M, Jefferies M, Hazelwood S, Dunlop AJ, Greenaway M, Haber P, Ezard N, Malcom A. Lintzeris N, et al. Among authors: jefferies m. Drug Alcohol Rev. 2020 Jan;39(1):55-65. doi: 10.1111/dar.13015. Epub 2019 Nov 27. Drug Alcohol Rev. 2020. PMID: 31774221
Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial.
Lintzeris N, Mills L, Dunlop A, Copeland J, Mcgregor I, Bruno R, Kirby A, Montebello M, Hall M, Jefferies M, Kevin R, Bhardwaj A; Agonist Replacement For Cannabis Dependence Study Group. (Arc-D). Lintzeris N, et al. Among authors: jefferies m. Drug Alcohol Depend. 2020 Oct 1;215:108220. doi: 10.1016/j.drugalcdep.2020.108220. Epub 2020 Aug 1. Drug Alcohol Depend. 2020. PMID: 32768992 Clinical Trial.
Assessing the concurrent validity, inter-rater reliability and test-re-test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations.
Deacon RM, Mammen K, Bruno R, Mills L, Dunlop A, Holmes J, Jefferies M, Hall M, Shakeshaft A, Farrell M, Graham R, Lintzeris N. Deacon RM, et al. Among authors: jefferies m. Addiction. 2021 May;116(5):1245-1255. doi: 10.1111/add.15331. Epub 2021 Jan 4. Addiction. 2021. PMID: 33201546
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
Mills L, Dunlop A, Montebello M, Copeland J, Bruno R, Jefferies M, Mcgregor I, Lintzeris N. Mills L, et al. Among authors: jefferies m. Subst Abuse Treat Prev Policy. 2022 Oct 8;17(1):67. doi: 10.1186/s13011-022-00493-z. Subst Abuse Treat Prev Policy. 2022. PMID: 36209081 Free PMC article. Clinical Trial.
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M, Byrne J, Bath N, Read P, Edwards M, Gorton C, Hayllar J, Cock V, Peterson S, Thomson C, Weltman M, Jefferies M, Wood W, Haber P, Ezard N, Martinello M, Maher L, Dore GJ; LiveRLife Study Group. Bajis S, et al. Among authors: jefferies m. J Viral Hepat. 2020 Mar;27(3):281-293. doi: 10.1111/jvh.13233. Epub 2019 Dec 6. J Viral Hepat. 2020. PMID: 31698545
69 results